Cema-cel treatment achieved minimal residual disease (MRD) clearance in 58.3% of patients compared to 16.7% under observation, with a 97.7% median reduction in circulating tumor DNA by day 45, indicating strong early biological activity. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to support its development, though these do not guarantee long-term efficacy. A fair-value estimate of $3.50 suggests about 61% upside potential, leading to a speculative Buy rating despite ongoing concerns about event-free survival (EFS) and dilution risks. The analysis emphasizes cautious optimism based on early clinical data and regulatory support.
Uber Technologies maintains a Buy rating amid stock volatility, driven by strong core business and strategic investments. The company is tackling autonomous vehicle risks by investing $10 billion and planning to integrate 120,000 AVs. Uber's global e...
Stifel Nicolaus increased its price target for Donaldson Company to $95, reflecting a 3.77% potential upside. Donaldson reported record fiscal 2026 results with $3.9 billion in sales, a 5% increase, and adjusted EPS up 8% to $3.98. The company also a...
Investors holding the Vanguard Total International Stock ETF (VXUS) inside IRAs lose the foreign tax credit on dividends because retirement accounts cannot claim this credit. Foreign governments withhold taxes on dividends before they reach the fund,...
Power Metallic Mines Inc. has initiated a $200,000 digital marketing campaign with Native Ads to promote its upcoming Mineral Resource Estimate (MRE) and Preliminary Economic Assessment (PEA). The campaign focuses on investor engagement through digit...
The NEOS Nasdaq-100 High Income ETF (QQQI) provides a monthly income that appears nearly tax-free to retirees, as much of the distribution is classified as return of capital (ROC). This ROC lowers the investor's cost basis rather than being taxed imm...
